Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Debt, Geopolitics, and Humanoid Robotics: Unlocking Productivity in a Changing World

    Explore one of our recent reports, which navigates the geopolitical race for humanoid dominance.

    Read more

  • Solving the Paternal Testing Hurdle in Prenatal Genetics

    Partner testing can slow prenatal carrier screening. Single-gene non-invasive prenatal testing uses one maternal blood draw to estimate fetal risk and speed counseling.

    Read more

  • The Economic Impact of AI in Healthcare

    AI is transforming healthcare, driving cost savings and improving patient care. Learn how this $1 trillion shift is reshaping the industry and creating opportunities for providers, patients, and investors.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures